Oct 22, 2026 • 8:00 am EDT Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
Sep 29, 2026 • 8:00 am EDT Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Sep 14, 2026 • 7:00 am EDT Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
Sep 11, 2026 • 4:01 pm EDT Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Aug 6, 2026 • 8:00 am EDT Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
Aug 4, 2026 • 8:30 am EDT Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Jul 28, 2026 • 8:00 am EDT Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Jul 6, 2026 • 8:00 am EDT Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
May 26, 2026 • 7:00 am EDT Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers